{"id":8865,"date":"2025-10-06T19:35:27","date_gmt":"2025-10-06T16:35:27","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8865"},"modified":"2025-10-06T19:35:27","modified_gmt":"2025-10-06T16:35:27","slug":"tavrtavi-in-europevs-savr-cardiologists-heart-surgeons-sound-alarm-over-widespread-use-of-tavr-in-low-risk-patients","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/tavrtavi-in-europevs-savr-cardiologists-heart-surgeons-sound-alarm-over-widespread-use-of-tavr-in-low-risk-patients\/","title":{"rendered":"TAVR(TAVI in Europe)vs. SAVR \u2014\u00a0 Cardiologists, heart surgeons sound alarm over widespread use of TAVR in low-risk patients"},"content":{"rendered":"
TAVR(TAVI in Europe)vs. SAVR \u2014<\/div>\n
<\/div>\n
Cardiologists, heart surgeons sound alarm over widespread use of TAVR in low-risk patients<\/div>\n
<\/div>\n
Source: Medical Commentary \u2013 October 4, 2025, from JACC & ACC report<\/div>\n
<\/div>\n
Keynotes :<\/div>\n
1-Background<\/div>\n
\u2022 Both TAVR (Transcatheter Aortic Valve Replacement) and SAVR (Surgical Aortic Valve Replacement) treat severe aortic stenosis.<\/span><\/div>\n
\u2022 TAVR use has grown rapidly \u2014 even in low-risk and younger patients (<65 years) \u2014 raising questions about long-term durability.<\/span><\/div>\n
<\/div>\n
2-Survival and Recovery<\/div>\n
(First 5 Years):<\/div>\n
\u2022 Survival is almost identical \u2248 70\u201375 % TAVR<\/span><\/div>\n
(vs \u2248 70\u201375 % SAVR)<\/div>\n
\u2022 Recovery is faster after TAVR<\/span><\/div>\n
(short hospital stay TAVR vs longer SAVR)<\/div>\n
\u2022 Bleeding is lower \u2248 5 % TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 % SAVR)<\/div>\n
\u2022 Atrial fibrillation is much less common in TAVR \u2248 5 %\u00a0<\/span><\/div>\n
(vs \u2248 30 % SAVR)<\/div>\n
\u2022 After a few months, doctors start to see some specific TAVR-related issues.<\/span><\/div>\n
<\/div>\n
3-TAVR-Specific Complications<\/div>\n
\u2022 Pacemaker rate: \u2248 20 % TAVR (vs \u2248 5 % SAVR):-<\/span><\/div>\n
\u2022 Main timing: within first 3\u20137 days post-TAVR<\/span><\/div>\n
\u2022 Most (\u2248 85 %) during index hospitalization<\/span><\/div>\n
\u2022 Few (\u2248 10\u201315 %) within first 30 days<\/span><\/div>\n
\u2022 Very rare (< 2 %) after 1 month<\/span><\/div>\n
\u2022 Paravalvular leak (PVL) \u2248 20 % TAVR<\/span><\/div>\n
(vs \u2248 3 % SAVR)<\/div>\n
\u2022 Stroke rate is slightly lower or similar with TAVR (\u22482\u20133% TAVR vs \u22483\u20134% SAVR), especially with newer-generation valve systems..<\/span><\/div>\n
\u2022 Major bleeding \u2248 5 % TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 % SAVR)<\/div>\n
\u2022 Early hospital mortality \u2248 1\u20132 % TAVR<\/span><\/div>\n
(vs \u2248 2\u20133 % SAVR)<\/div>\n
<\/div>\n
4-Medium- and Long-Term Course (5\u201310 Years)<\/div>\n
\u2022 From year 2 to 5, valve function stays good, but some patients start to see thickened leaflets or rising gradients \u2248 10 % TAVR<\/span><\/div>\n
(vs \u2248 5 % SAVR)<\/div>\n
\u2022 After \u2248 10 years, redo procedures may be needed in \u2248 15\u201320 % TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 % SAVR)<\/div>\n
\u2022 Durability averages \u224810 years for TAVR (vs \u224810\u201315 years for SAVR using bioprosthetic valves, while mechanical valves may last >20 years \u2014 overall, surgical valve replacement remains more durable).<\/span><\/div>\n
\u2022 Full 10-year data from PARTNER 3 and Evolut Low Risk are expected around 2030.<\/span><\/div>\n
<\/div>\n
5-Surgical (SAVR) Profile<\/div>\n
\u2022 Invasiveness: higher (open-chest operation).<\/span><\/div>\n
\u2022 Pacemaker need \u2248 5 % SAVR<\/span><\/div>\n
(vs \u2248 20 % TAVR)<\/div>\n
\u2022 Leak around valve \u2248 3 % SAVR<\/span><\/div>\n
(vs \u2248 20 % TAVR)<\/div>\n
\u2022 Atrial fibrillation \u2248 30 % SAVR<\/span><\/div>\n
(vs \u2248 5 % TAVR)<\/div>\n
\u2022 Major bleeding \u2248 10\u201315 % SAVR<\/span><\/div>\n
(vs \u2248 5 % TAVR)<\/div>\n
\u2022 Durability \u2248 10\u201315 years SAVR<\/span><\/div>\n
(vs \u2248 8\u201310 years TAVR)<\/div>\n
\u2022 Redo need \u2248 10\u201315 % by 15 yrs SAVR<\/span><\/div>\n
(vs \u2248 15\u201320 % by 10 yrs TAVR)<\/div>\n
<\/div>\n
6-Patient Counseling<\/div>\n
\u2022 TAVR: easier, faster, and ideal for older \/ high-risk patients.<\/span><\/div>\n
\u2022 SAVR: longer recovery but stronger and more durable for younger \/ low-risk patients.<\/span><\/div>\n
\u2022 The heart team should clearly explain short-term comfort (TAVR) versus long-term durability (SAVR) before any decision.<\/span><\/div>\n
<\/div>\n
7-Main Differences Summary:<\/div>\n
\u2022 Survival is the same \u2248 70\u201375 % TAVR<\/span><\/div>\n
(vs \u2248 70\u201375 % SAVR)<\/div>\n
\u2022 Pacemaker need is higher \u2248 20 % TAVR<\/span><\/div>\n
(vs \u2248 5 % SAVR)<\/div>\n
\u2022 Leak around valve is higher \u2248 20 % TAVR<\/span><\/div>\n
(vs \u2248 3 % SAVR)<\/div>\n
\u2022 Atrial fibrillation is lower \u2248 5 % TAVR<\/span><\/div>\n
(vs \u2248 30 % SAVR)<\/div>\n
\u2022 Bleeding is lower \u2248 5 % TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 % SAVR)<\/div>\n
\u2022 Durability shorter \u2248 8\u201310 yrs TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 yrs SAVR)<\/div>\n
\u2022 Redo procedure more common \u2248 15\u201320 % TAVR<\/span><\/div>\n
(vs \u2248 10\u201315 % SAVR)<\/div>\n
<\/div>\n
https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2025.08.003<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

TAVR(TAVI in Europe)vs. SAVR \u2014 Cardiologists, heart surgeons sound alarm over widespread use of TAVR in low-risk patients Source: Medical Commentary \u2013 October 4, 2025, from JACC & ACC report Keynotes : 1-Background \u2022 Both TAVR (Transcatheter Aortic Valve Replacement) and SAVR (Surgical Aortic Valve Replacement) treat severe aortic stenosis. \u2022 TAVR use has grown […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8865","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8865"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8865\/revisions"}],"predecessor-version":[{"id":8866,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8865\/revisions\/8866"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}